Table 1.
Clinicopathological and molecular associations of YBX3 and ZRSR2 promoter hypermethylation in the Cancer Genome Atlas Research Network acute myeloid leukemia (AML) cohort
| YBX3 hypermethylation | ZRSR2 hypermethylation | |||||
|---|---|---|---|---|---|---|
| Present (n = 11) | Absent (n = 162) | P-value | Present (n = 7) | Absent (n = 166) | P-value | |
| Age, years | ||||||
| Median(range) | 39 (18–68) | 59 (18–88) | 0.0399 | 53 (23–66) | 59 (18–88) | 0.1316 |
| Sex, n (%) | ||||||
| Male | 7 (64) | 86 (53) | 0.4971 | 7 (100) | 86 (52) | 0.0079 |
| Female | 4 (36) | 76 (47) | 0 (0) | 80 (48) | ||
| WBC, k/μL | ||||||
| Median (range) | 27 (3–203) | 16 (1–297) | 0.5248 | 22 (1–88) | 18 (1–297) | 0.8154 |
| Blast, % | ||||||
| Median (range) | 62 (34–86) | 72 (0–100) | 0.2908 | 72 (35–86) | 71 (0–100) | 0.9025 |
| Subtypes, n (%) | ||||||
| M0 | 1 (10) | 15 (9) | 0.6555 | 0 (0) | 16 (10) | 0.8374 |
| M1 | 2 (18) | 40 (25) | 1 (14) | 41 (25) | ||
| M2 | 5 (45) | 34 (21) | 3 (43) | 36 (22) | ||
| M3 | 0 (0) | 16 (10) | 1 (14) | 15 (9) | ||
| M4 | 3 (27) | 32 (20) | 2 (29) | 33 (20) | ||
| M5 | 0 (0) | 18 (11) | 0 (0) | 18 (11) | ||
| M6 | 0 (0) | 2 (1) | 0 (0) | 2 (1) | ||
| M7 | 0 (0) | 3 (2) | 0 (0) | 3 (2) | ||
| Not classified | 0 (0) | 2 (1) | 0 (0) | 2 (1) | ||
| Cytogenetic risks, n (%) | ||||||
| Low | 0 (0) | 32 (20) | 0.2065 | 3 (43) | 29 (18) | 0.2468 |
| Intermediate | 9 (82) | 94 (58) | 3 (43) | 100 (60) | ||
| High | 2 (18) | 34 (21) | 1 (14) | 35 (21) | ||
| Not available | 0 (0) | 2 (1) | 0 (0) | 2 (1) | ||
| FLT3 mutation, n (%) | ||||||
| Mutant | 1 (9) | 49 (30) | 0.1763 | 2 (29) | 48 (29) | 0.3163 |
| Wild-type | 9 (82) | 107 (66) | 5 (71) | 111 (67) | ||
| Not determined | 1 (9) | 6 (4) | 0 (9) | 7 (4) | ||
| RAS mutation, n (%) | ||||||
| Mutant | 0 (0) | 9 (6) | 1.0000 | 0 (0) | 9 (5) | 1.0000 |
| Wild-type | 11 (100) | 150 (92) | 7 (100) | 154 (93) | ||
| Not determined | 0 (0) | 3 (2) | 0 (0) | 3 (2) | ||
| DNMT3A mutation, n (%) | ||||||
| Mutant | 2 (18) | 40 (25) | 1.0000 | 0 (0) | 42 (25) | 0.2027 |
| Wild-type | 9 (82) | 122 (75) | 7 (100) | 124 (75) | ||
| NPMc status, n (%) | ||||||
| Positive | 0 (0) | 42 (26) | 0.0708 | 1 (14) | 41 (25) | 1.0000 |
| Negative | 11 (100) | 117 (72) | 6 (86) | 122 (73) | ||
| Not determined | 0 (0) | 3 (2) | 0 (0) | 3 (2) | ||
Significant P-values are in bold. M0, AML with minimal differentiation; M1, AML without differentiation; M2, AML with maturation; M3, acute promyelocytic leukemia; M4, acute myelomonocytic leukemia; M5, acute monoblastic and monocytic leukemia; M6/M7, acute erythroid leukemia/acute megakaryoblastic leukemia; NPMc, cytoplasm-dislocalized leukemic nucleophosmin protein.